Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
McKesson
Dow
Harvard Business School
Julphar
Moodys
Deloitte
Argus Health
Teva

Generated: June 25, 2018

DrugPatentWatch Database Preview

Naloxegol oxalate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for naloxegol oxalate and what is the scope of naloxegol oxalate freedom to operate?

Naloxegol oxalate
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Naloxegol oxalate has one hundred and two patent family members in thirty-seven countries.

There are two drug master file entries for naloxegol oxalate. Two suppliers are listed for this compound.
Summary for naloxegol oxalate
Pharmacology for naloxegol oxalate
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Synonyms for naloxegol oxalate
(4R,4aS,7S,7aR,12bS)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
(5alpha,6alpha)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol
1354744-91-4
4,5alpha-epoxy-6alpha-((3,6,7,12,15,18,21-Heptaoxadocosyl)oxy)-17-(prop-2-enyl)morphinan-3,14-diol hydrogen ethanedioate
44T7335BKE
65I14TNM33
854601-70-0
AKOS030526444
AKOS030526932
AZ-13337019
AZ-13337019 oxalate
AZ13337019
AZ13337019 oxalate
CHEBI:82975
CHEMBL2219416
CHEMBL2219418
CS-4987
CS-5349
D07LCF
D10375
D10479
DB09049
DTXSID50159395
DTXSID80234684
GTPL7539
HSDB 8338
HY-A0118
HY-A0118A
MolPort-046-033-545
Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)- 17-(2-propenyl)-, (5alpha,6alpha)-
Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5alpha,6alpha)-, ethanedioate (1:1)
Movantik
moventig
Moventig (TN)
Naloxegol
Naloxegol (oxalate)
Naloxegol (USAN/INN)
Naloxegol [USAN:INN]
Naloxegol oxalate (USAN)
Naloxegol oxalate [USAN]
Naloxegol Oxalate(NKTR-118)
NKTR 118
NKTR-118
NKTR-118 oxalate
NKTR-118-oxalate
NKTR118
SCHEMBL19433066
UNII-44T7335BKE
UNII-65I14TNM33
ZINC95564694

US Patents and Regulatory Information for naloxegol oxalate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for naloxegol oxalate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,349,307 Polymer conjugates of opioid antagonists ➤ Sign Up
2,015,197,470 ➤ Sign Up
8,034,825 Chemically modified small molecules ➤ Sign Up
9,388,104 Chemically modified small molecules ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for naloxegol oxalate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
4 5008-2015 Slovakia ➤ Sign Up PRODUCT NAME: OXALAT NALOXEGOLU; REGISTRATION NO/DATE: EU/1/14/962 20141210
2015 00028 Denmark ➤ Sign Up PRODUCT NAME: OXYLATSALT AF NALOXEGOL; REG. NO/DATE: EU/1/14/962 20141210
702 Luxembourg ➤ Sign Up PRODUCT NAME: NALOXEGOL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (MOVENTIG); FIRST REGISTRATION: 20141210
2015019,C1694363 Lithuania ➤ Sign Up PRODUCT NAME: NALOKSEGOLAS, KONKRECIAI NALOKSEGOLO OKSALATO DRUSKA; REGISTRATION NO/DATE: EU/1/14/962 20141208
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fuji
US Department of Justice
AstraZeneca
Cerilliant
Queensland Health
Dow
QuintilesIMS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.